Trials / Not Yet Recruiting
Not Yet RecruitingNCT06305897
Evaluation of the Tolerance (Main Objective) and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots (Solar and Senile Lentigines, Post-inflammatory Hyperpigmentation) on the Face
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Cryonove Pharma · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The goal of this clinical trial is to compare the 3 different prototype of cyto-selective cryotherapy devices (name of the devices : CRYONOVE) use in brown spots on the face of subject from different ethnicities. The main questions it aims to answer are: * the tolerance of 3 prototypes of cyto-selective cryotherapy treatments * the performance of 3 prototypes of cyto-selective cryotherapy treatments Participants will be treated for each spots with a definied prototype during 6 treatment visits. Researchers will compare the tolerance and performance of the 3 prototypes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | CRYONOVE (EC14_4osc) | The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC14). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos). |
| DEVICE | CRYONOVE (EC+05_1osc) | The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC05\_1osc). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos). |
| DEVICE | CRYONOVE (EC+05_2osc) | The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC05\_2osc). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos). |
Timeline
- Start date
- 2024-04-01
- Primary completion
- 2024-12-01
- Completion
- 2024-12-01
- First posted
- 2024-03-12
- Last updated
- 2024-04-17
Source: ClinicalTrials.gov record NCT06305897. Inclusion in this directory is not an endorsement.